Health is said to be the biggest wealth in human life and when any issue occurs to our health, day-to-day life turns out tougher. Mild to severe chronic diseases demand remedies and the new-age bio-science has successfully brought solutions to that. Transcell Biologics is a biotech company that offers the vision of translating stem cell technology and its real-time applications for treating chronic diseases from its two regenerative medicine programs. One of the programs is a novel cell-based formula to treat Alzheimer’s disease and the other one is regenerative medicinal approach to address death sentences like muscular dystrophies.
“Under our parent entity, we have two subsidiaries: One is Transcell Biolife and the other one in Transcell Oncologics,” says Dr. Subhadra Dravida, the Founder, and CEO, Transcell Biologics. Transcell Biolife is however a next-generation biobank meant for the intended applications. It deals with biobanking both the processed biosamples like cord, tooth, apheresized products and the derived de-identified bio-data like imprints.
Additionally, there are two process derivatives developed as product technologies: TRUCB - a novel plasma formula superior to recovered plasma to support the plasma fractionation industry developing certain therapeutic proteins. The other one is BioActive Regenerative Tooth Innovation (BARTI)- and next-A stem cell implant bio-complex for periodontal applications.
“Transcell Oncologics has in-house drug discovery engine that has endured certain early breakthrough data on novel druggable molecules to treat solid metastatic cancers along with two application ready verticals”, Subhadra adds. Out of these two, one is branded as Hemato personalizing hematopoietic stem and cell transplantations treating blood and related disorders.
The other vertical is a science exchange registered valise named Transtoxbio with an all- new league of human surrogate cell and tissue-based micro physiological systems to test and predict certain safety and efficacy concerns of pharma and biopharmaceutical candidates.
Transtoxbio aspires to offer Safety Efficacy Testing as a Solution to the global industry. NeuroSAFE developed in partnership with Wipro for testing vaccine safety is a workstation solution built on human induced pluripotent stem cell platform technology fortified with Robotic Process Automation, AI and MLdigital analytic tools integrated in the user’s workflow – A Gen Z New Approach Methodology to predict human neurovirulence and neurotoxicity of vaccines and drugs,being encouraged by the global regulators to adopt by the industry.
Offering Excellence Through Research And Development
As an innovative biotech company that has special imagination alongside domain expertise, faith in new possibilities, Transcell continuously dives into the discovery and development engine to deliver unique and disruptive new age solutions superimposing innovation and commerce. The company uses it’s flagship proprietary primary, progenitor cell-based technology along with other biotechnological processes, industrial, manufacturing, and production technologies that are relevant to this field. It integrates artificial intelligence and machine learning, robotic process automation like digital technology when and wherever required as complementary components in the journey. Armed with passionate leadership teams, the company is focused to deliver cure options addressing cancers, neuro-muscular disorders, covid-19 like indications, medical needs through cell technologies collaborating with clinicians and patient communities. “Science based translational research has been the DNA of Transcell and I believe that one has to have the required imagination alongside knowledge, operational skill sets, infrastructure to deliver quality with speed.
I come from the school and clan that believes speed matters as discovery can’t wait”, Subhadra explains. Transcell’s humble beginning as an R&D unit resonates with it’s purpose of existence. All along, the group has reached out for academic collaborations with Institutes of Life Sciences, reputed universities, medical institutions to constantly validate the applications developed while connecting with the user community in India and abroad. Transcell as a group wants to scale up the services and products, it’s operations to the next level as part of it’s blue ocean strategy. The group is also very keen to find cure options for cancers and neurodegenerative diseases based on it’s early breakthrough data and original hypothesis. Collaborating with strategic teams (domestic and global)is the success mantra in Transcell’s expedition formula that is aimed at organic business growth.As a group, the company has witnessed a sensible, defensible growth in revenue generation and is keen to see the impact of adding value to the markets through its products and services.
Transcell has it’s own master plan, stands for spesh imagination alongside knowledge, domain expertise, reasoning and faith in new possibilities
Dr. Subhadra Dravida, Founder & CEO
Dr. S Dravida (Ph.D),is an entrepreneurial technocrat on the global platform in countries like the US, Canada, and India. She has immense knowledge, hands on experience in stem cell research/biobanking and product development, adult stem cell technologies, predictive platforms and screening, large-scale preparations of primary cells, cryopreservation technology, big data, drug discovery, pre-clinical process, clinical trials etc.
.jpg "Technology in Cancer Care: A story of evolving paradigms")
.jpg "Bringing Shop Floor to Manufacturer's palm: Smart Factory Solutions for tomorrow")
